To download the webinar recording, complete the form.
Late-stage oncology trials face some of the most pressing challenges in drug development. Sites are often overwhelmed, patient eligibility requirements are increasingly complex, and competition for both sites and participants continues to grow. Overcoming these hurdles demands innovative approaches that place the patient journey at the center of planning and execution.
This webinar will feature perspectives on rethinking site selection, feasibility and patient recruitment in ways that better align with the realities of modern oncology research. The featured speakers will explore how a paradigm shift in site selection methodology can open new opportunities for accessing the right patients. How real-world considerations influence both recruitment and retention. In addition, the discussion will highlight strategies for reducing site burden and strengthening partnerships through training, streamlined processes, and the integration of decentralized elements.
Through practical insights, attendees will gain a forward-looking perspective on how oncology trials can evolve to improve efficiency and patient outcomes in a highly competitive landscape.
Key Insights from the Webinar
- How a patient pathway-focused approach can improve site selection in late-stage oncology trials
- Strategies to overcome challenges in oncology patient recruitment and retention
- Best practices for reducing site burden and strengthening site partnerships
Ready to transform your oncology trial outcomes? Complete the form to download the webinar recording now and access actionable strategies and expert insights you can apply today.
Speakers
Sandra Olthof, MSc, Global Operations Head, Oncology/Hematology, Allucent
Sandra Olthof, MSc, is the Global Operations Head of Oncology/Hematology at Allucent, where she leads cross-functional project teams, manages oncology and hematology portfolios and drives process optimization and client satisfaction within Clinical Trial Operations. With over 15 years of experience in clinical oncology, she has successfully led global Phase I–IV trials across immuno-oncology and hematologic oncology, ensuring operational excellence and high-quality delivery.
Almenia Garvey, MSc, Senior Director, Global Feasibility/Site Engagement, Allucent
Almenia Garvey is the Senior Director of Global Feasibility/Site Engagement at Allucent. With over 25 years of experience in clinical research, Almenia has been involved in numerous projects that integrate healthcare and technology, such as EHR2EDC. Her expertise lies in site selection strategy, investigator identification and investigator relationship management. Almenia serves on the Board of Directors for Nvolve, a non-profit organization dedicated to preparing young women for STEM careers. Additionally, she contributes her expertise as an advisory board member for CISCRP (Center for Information & Study on Clinical Research Participation).
Kitty Oudijk, MSc, Associate Director, Patient Engagement, Allucent
Kitty Oudijk, MSc, is the Associate Director of Patient Engagement at Allucent. With over 18 years of professional experience in the field of clinical research, Kitty is responsible for managing the patient recruitment strategy from proposal to study close-out, including creating the strategic plan and tactics that will be utilized. She oversees the coordination and management of the PE strategy by coordinating all aspects from in-house material creation to vendor management of PE vendors, ensuring the recruitment targets are met and preferably achieved ahead of target. Her focus is on projects in various indications with a range of investigational drugs, from early Phase/FIH to large international Phase III studies.
To view the content, please fill out the form below.
Share This
